Fort Washington Investment Advisors Inc. OH Increases Position in Certara, Inc. $CERT

Fort Washington Investment Advisors Inc. OH increased its holdings in Certara, Inc. (NASDAQ:CERT) by 17.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,675,543 shares of the company’s stock after acquiring an additional 402,720 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Certara were worth $15,251,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. grew its stake in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Certara during the 2nd quarter valued at approximately $83,000. Finally, Curated Wealth Partners LLC acquired a new stake in shares of Certara during the fourth quarter worth approximately $89,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

CERT stock opened at $5.83 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The firm has a market cap of $906.20 million, a P/E ratio of -58.25 and a beta of 1.49. Certara, Inc. has a 12-month low of $4.45 and a 12-month high of $13.88. The stock’s 50 day simple moving average is $5.58 and its 200 day simple moving average is $6.92.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business’s revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the business earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities research analysts predict that Certara, Inc. will post 0.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. KeyCorp decreased their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Monday, April 13th. BMO Capital Markets dropped their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Barclays cut their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara currently has an average rating of “Hold” and an average target price of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.